The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

Clinical stem cell applications are the fruit of research efforts that have deep roots—years of research at the design and manufacturing level. It is from this ground that production processes for therapeutic stem cells are emerging like so many tender shoots. Ultimately, these processes will be scaled up and deployed widely, yielding a bumper crop of stem cell therapies.

From tissue engineering and immunotherapy to cell reprogramming and regenerative medicine, advances in stem cell technologies are being developed across diverse clinical indications and scientific disciplines. Dedicated researchers have navigated scientific and regulatory hurdles. Although they have few approved applications to their credit, these researchers are finding that their persistence is beginning to pay off. Several stem cell-based therapies are now in the clinical phase of investigation.

A particularly promising approach is genome editing. “The whole area of genome editing in stem cells is enormously broad and potentially curative in many diseases,” notes Edward Lanphier, president and CEO of Sangamo Biosciences.

Read full, original post: Reaping What Stem Cell Technology Sows